A Study on the Efficacy of Proton Pump Inhibitors in Helicobacter pylori-Negative Primary Care Patients with Dyspepsia in Japan
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: There have been few studies on the efficacy of proton pump inhibitors and the doses required to treat dyspeptic symptoms observed in clinical practice. The aim of this study was to compare the efficacy of different doses of omeprazole and different administration methods in Helicobacter pylori-negative, dyspeptic patients. Methods:Patients with chronic upper abdominal symptoms within the previous 3 months were randomly divided into three groups: a daily, omeprazole 20 mg treatment group (OPZ20, n=61); a daily, omeprazole 10 mg treatment group (OPZ10, n=72); and an on-demand omeprazole 20 mg treatment group (on-demand, n=62). After 4 weeks of administration of the drug, symptom improvement rates were evaluated based on the Overall Global Severity score. Results: The rates of symptom improvement after 4 weeks of treatment were 65.6% (40/61) in the OPZ20 group, 47.2% (34/72) in the OPZ10 group, and 50.0% (31/62) in the on-demand group. The OPZ20 group exhibited a significantly higher improvement rate (p=0.034) than the OPZ10 group. The OPZ20 group had significant improvements in regurgitation, postprandial fullness, vomiting, and bloating compared with the OPZ10 group. Conclusions: Daily treatment with 20 mg of omeprazole was efficient in treating upper abdominal symptoms. Trial registration: ClinicalTrials.gov, number UMIN000002621
Abstract
Background/Aims: There have been few studies on the efficacy of proton pump inhibitors and the doses required to treat dyspeptic symptoms observed in clinical practice. The aim of this study was to compare the efficacy of different doses of omeprazole and different administration methods in Helicobacter pylori-negative, dyspeptic patients. Methods:Patients with chronic upper abdominal symptoms within the previous 3 months were randomly divided into three groups: a daily, omeprazole 20 mg treatment group (OPZ20, n=61); a daily, omeprazole 10 mg treatment group (OPZ10, n=72); and an on-demand omeprazole 20 mg treatment group (on-demand, n=62). After 4 weeks of administration of the drug, symptom improvement rates were evaluated based on the Overall Global Severity score. Results: The rates of symptom improvement after 4 weeks of treatment were 65.6% (40/61) in the OPZ20 group, 47.2% (34/72) in the OPZ10 group, and 50.0% (31/62) in the on-demand group. The OPZ20 group exhibited a significantly higher improvement rate (p=0.034) than the OPZ10 group. The OPZ20 group had significant improvements in regurgitation, postprandial fullness, vomiting, and bloating compared with the OPZ10 group. Conclusions: Daily treatment with 20 mg of omeprazole was efficient in treating upper abdominal symptoms. Trial registration: ClinicalTrials.gov, number UMIN000002621
참고문헌 (33)
- Talley NJ, "Functional gastroduodenal disorders", Gut, (45 Suppl 2), pp.II37~II42 (1999)
- Tack J, "Functional gastroduodenal disorders", Gastroenterology, 130, pp.1466~1479 (2006)
- Kawamura A, "Prevalence of functional dyspepsia and its relationship with Helicobacter pylori infection in a Japanese population", J Gastroenterol Hepatol, 16, pp.384~388 (2001)
- Stanghellini V, "Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic", International Gastroenterology Surveillance Study (DIGEST), 1999, pp.231, 20~28
- Jones RH, "Dyspepsia in England and Scotland", Gut, 31, pp.401~405 (1990)
- Talley NJ, "Dyspepsia and dyspepsia subgroups: a population-based study", 102(4 Pt 1), pp.1259~1268 (1992)
- Fass R, "Proton pump inhibitor failure: what are the therapeutic options?", Am J Gastroenterol, (104 Suppl 2), pp.S33~S38 (2009)
- Peura DA, "Proton pump inhibitors: effective first-line treatment for management of dyspepsia", Dig Dis Sci, 52, pp.983~987 (2007)
- North of England Dyspepsia Guideline Development Group, "Dyspepsia: managing dyspepsia in adults in primary care" (2004), University Newcastle upon Tyne
- Talley NJ, "Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)", Aliment Pharmacol Ther, 12, pp.1055~1065 (1998)
- Blum AL, "Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group", Gut, 47, pp.473~480 (2000)
- Wong WM, "Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients", Gut, 51, pp.502~506 (2002)
- Moayyedi P, "Pharmacological interventions for non-ulcer dyspepsia", Cochrane Database Syst Rev, (4), pp.CD001960~ (2006)
- Veldhuyzen van Zanten SJ, "Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis", Am J Gastroenterol, 96, pp.689~696 (2001)
- Moayyedi P, "The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis", Gastroenterology, 127, pp.1329~1337 (2004)
- Wang WH, "Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials", Clin Gastroenterol Hepatol, 5, pp.178~185 (2007)
- Veldhuyzen van Zanten SJ, "A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study", Am J Gastroenterol, 100, pp.1477~1488 (2005)
- Junghard O, "Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non ulcer dyspepsia", Eur J Surg Suppl, (583), pp.106~111 (1998)
- Graham DY, "Rapid detection of anti-Helicobacter pylori IgG in urine using immunochromatography", Aliment Pharmacol Ther, 15, pp.699~702 (2001)
- Sjostedt S, "Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis", Aliment Pharmacol Ther, 22, pp.183~191 (2005)
- Akamatsu T, "Introduction of an examination and treatment for Helicobacter pylori infection in high school health screening", J Gastroenterol, 46, pp.1353~1360 (2011)
- Nakajima S, "Changes in the prevalence of Helicobacter pylori infection and gastrointestinal diseases in the past 17 years", J Gastroenterol Hepatol, (25 Suppl 1), pp.S99~S110 (2010)
- Kawai T, "Helicobacter pylori infection and reflux esophagitis in young and middle-aged Japanese subjects", J Gastroenterol Hepatol, (25 Suppl 1), pp.S80~S85 (2010)
- Manabe N, "Changes of upper gastrointestinal symptoms and endoscopic findings in Japan over 25 years", Intern Med, 50, pp.1357~1363 (2011)
- Miyoko Yamaoka, "Prevalence of Subjects at a High or Very High Risk of Gastric Cancer in Japan", Gut and Liver, 3(2), pp.95~100 (2009), 거트앤리버 발행위원회
- Tack J, "Pathophysiology and treatment of functional dyspepsia", J Clin Gastroenterol, 39(5 Suppl 3), pp.S211~S216 (2005)
- Tack J, "Pathophysiology and treatment of functional dyspepsia", Gastroenterology, 127, pp.1239~1255 (2004)
- Kusunoki H, "Efficacy of Rikkunshito, a traditional Japanese medicine (Kampo), in treating functional dyspepsia", Intern Med, 49, pp.2195~2202 (2010)
- Grudell AB, "Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study", Aliment Pharmacol Ther, 24, pp.1037~1043 (2006)
- Manabe N, "Diagnosis and treatment of dyspeptic patients in Japan", J Gastroenterol Hepatol, (26 Suppl 3), pp.27~31 (2011)
- Pace F, "Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken ‘on-demand’", Aliment Pharmacol Ther, 26, pp.195~204 (2007)
- Moayyedi P, "Gastro-oesophageal reflux disease", Lancet, 367, pp.2086~2100 (2006)
- Donnellan C, "Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease", Cochrane Database Syst Rev, (2), pp.CD003245~ (2005)